Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

PURPOSE: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥...

Descripción completa

Detalles Bibliográficos
Autores principales: Westin, Jason R., Locke, Frederick L., Dickinson, Michael, Ghobadi, Armin, Elsawy, Mahmoud, van Meerten, Tom, Miklos, David B., Ulrickson, Matthew L., Perales, Miguel-Angel, Farooq, Umar, Wannesson, Luciano, Leslie, Lori, Kersten, Marie José, Jacobson, Caron A., Pagel, John M., Wulf, Gerald, Johnston, Patrick, Rapoport, Aaron P., Du, Linqiu, Vardhanabhuti, Saran, Filosto, Simone, Shah, Jina, Snider, Julia T., Cheng, Paul, To, Christina, Oluwole, Olalekan O., Sureda, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183830/
https://www.ncbi.nlm.nih.gov/pubmed/36999993
http://dx.doi.org/10.1158/1078-0432.CCR-22-3136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183830/
https://www.ncbi.nlm.nih.gov/pubmed/36999993
http://dx.doi.org/10.1158/1078-0432.CCR-22-3136

Ejemplares similares